Physician profile
Jay B Herman
NPI 1477574234
$13,315.77
in general payments reported to CMS, 2019-2025
40 companies · $1,546 in 2025
The $1,546 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,034 · 2020: $1,483 · 2021: $1,991 · 2022: $1,664 · 2023: $3,304 · 2024: $1,294 · 2025: $1,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,296 · Consulting Fee: $1,640 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,295.89 |
| Consulting Fee | $1,640.00 |
| Education | $208.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $2,117.78 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $1,988.87 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Pfizer INC. | $1,958.96 | 2019-2025 | |
| Boston Scientific Corporation | $1,879.25 | 2019-2024 | Ams 700 |
| Bayer Healthcare Pharmaceuticals INC. | $917.17 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $565.97 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $439.89 | 2023-2025 | Orgovyx |
| Tolmar, INC. | $369.95 | 2023-2025 | Eligard, Jatenzo, Rubraca |
| Biofire Diagnostics, LLC | $300.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $292.14 | 2019-2025 | Erleada |
| Progenics Pharmaceuticals, INC. | $258.98 | 2022-2025 | Pylarify |
| Astellas Pharma Global Development | $258.33 | 2022-2023 | Xtandi |
| Davol INC. | $235.13 | 2020-2023 | Phasix Mesh |
| Merck Sharp & Dohme LLC | $233.92 | 2020-2025 | Keytruda, Lynparza |
| Urogen Pharma, INC. | $187.62 | 2021-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $186.15 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $146.14 | 2019-2020 | |
| Medivation Services LLC | $123.81 | 2023 | |
| Myovant Sciences INC. | $113.88 | 2021 | |
| Urovant Sciences INC | $92.57 | 2021-2022 | |
| Medtronic, INC. | $80.00 | 2022-2023 | Surgipro Ll |
| Neotract INC. | $78.79 | 2019 | |
| Dentsply Ih INC. | $64.78 | 2019-2020 | |
| Blue Earth Diagnostics | $60.00 | 2020-2021 | |
| Verity Pharmaceuticals INC. | $52.52 | 2021 | |
| Myriad Genetic Laboratories, INC. | $35.53 | 2022 | |
| Ferring Pharmaceuticals INC. | $35.13 | 2019 | |
| Pharmaand Gmbh | $29.87 | 2025 | Rubraca |
| Telix Pharmaceuticals | $29.34 | 2023 | Illuccix |
| C. R. Bard, INC. & Subsidiaries | $24.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.50 | 2025 | |
| Procept Biorobotics Corporation | $20.33 | 2025 | |
| Innovation Technologies INC | $19.84 | 2024 | Irrisept |
| Alexion Pharmaceuticals, INC. | $17.25 | 2022 | |
| Accord Healthcare, INC. | $16.86 | 2022 | |
| Immunitybio, INC. | $16.83 | 2024 | |
| Olympus America INC. | $16.34 | 2019 | |
| Metuchen Pharmaceuticals | $16.27 | 2019 | |
| Axonics, INC. | $14.28 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.